The Results Report highlights the significant strides the Global Fund partnership has made in the fight against HIV, tuberculosis (TB) and malaria in 2023.

The results we have achieved in the last year build on an extraordinary record of progress: Since 2002, our partnership has cut the combined death rate from AIDS, TB and malaria by 61%. In 2023, we reached a new milestone on our journey to end HIV, TB and malaria as public health threats: We put more people on antiretroviral treatment for HIV than ever before, we found and put on treatment more people with TB than ever before, and we distributed a record number of mosquito nets to prevent malaria.

In 2023 the Global Fund made an unprecedented level of investments to build strong health and community systems, mitigating the impact of today’s global crises on the health programs that we fund. We played a critical role in supporting countries and communities to advance human rights and gender equality by breaking down barriers to health and ensuring access to lifesaving care to those who need it most.


Key Results and Lives Saved

Since our inception in 2002, health programs supported by the Global Fund partnership have saved 65 million lives. 



Key Results:




The coverage of key treatment and prevention interventions for HIV, TB and malaria in countries where the Global Fund invests has increased significantly since our founding. In 2023, 78% of people living with HIV were on antiretroviral therapy, up from 22% in 2010. TB treatment coverage reached 70% in 2022, up from 45% in 2010. The percentage of the population with access to a long-lasting insecticide-treated net reached 57% in 2022, up from 30% in 2010.

By putting people and communities at the center of all our work, we continued to deliver on our promise to save lives from HIV, TB and malaria and help countries build stronger and more inclusive health and community systems. Our investments have played a pivotal role in helping to increase life expectancy in low- and middle-income countries. Millions of people in sub-Saharan Africa are living longer, largely because of the gains made in the fight against HIV, TB and malaria.

We measure our progress against the targets in the global plans for HIV, TB and malaria and in the Sustainable Development Goal (SDG) 3 of health and well-being for all. Our achievements are the result of efforts by a wide array of actors comprising the Global Fund partnership, including governments, multilateral agencies, bilateral partners, the private sector, civil society groups, and people and communities affected by the three diseases.

   








The world continues to make remarkable gains against HIV – the end of AIDS as a public health threat is within reach.

In 2023, the Global Fund continued to invest strongly in HIV treatment, including interventions focused on enrolling and maintaining more people on lifesaving care. Twenty-five million people were on lifesaving antiretroviral therapy in countries where the Global Fund invests in 2023, up from 17.5 million in 2017. In 2023, the Global Fund, together with partners and generic pharmaceutical manufacturers, secured a price reduction of 25% for the preferred first-line HIV treatment, enabling governments to invest in other critical areas of their HIV programs, save more lives and reduce new infections.

Our investments in HIV prevention focused on increasing access to the interventions that have the greatest impact on reducing new HIV infections. In the countries where we invest, 17.9 million people were reached with HIV prevention services, including 8 million people from key populations and 8.5 million young people. We continued to support countries to address societal and structural factors that fuel the HIV epidemic, promoting and protecting human rights and addressing other inequalities that predispose people to the virus.


All data is based on estimates from UNAIDS 2024 release. Global Fund disbursements are available on the Global Fund Data Explorer. The denominator for the three 95s is people living with HIV. The data for disease burden estimate and service coverage reflects that available from UNAIDS at the time of publication. Global Fund Regional Groupings.


Global Fund investments not only drive progress in tackling HIV, but also contribute to building strong, equitable and resilient health and community systems. In 2023, investments in training health care workers, improving laboratory infrastructure and integrating HIV services into broader health systems accelerated country-led responses to HIV while supporting progress in the fight against other diseases and strengthening pandemic preparedness.

But our fight isn’t over yet. In 2023, 39.9 million people were living with HIV globally, 1.3 million people were newly infected with the virus, and 630,000 people died of AIDS-related causes. We must significantly scale up efforts and resources if the world is to meet the SDG 3 target of ending AIDS as a public health threat by 2030. 




HIV Infections Among Adolescent Girls and Young Women

Gender inequality has long been recognized as a powerful driver of the HIV epidemic. Adolescent girls and young women (aged 15 to 24) are still disproportionately affected. But Global Fund investments in 13 priority countries have led to a 69% reduction in the HIV incidence rate amongst adolescent girls and young women in these countries since 2010. In 2023, 2.6 million adolescent girls and young women were reached with HIV prevention programs in these priority countries. The Global Fund has also invested in HIV treatment and prevention programs focusing on boys and men, including voluntary medical male circumcision as well as efforts to address harmful cultural and social norms that influence HIV transmission.

 



Trends in HIV Burden

In countries where the Global Fund invests, AIDS-related deaths have been reduced by 73% since the Global Fund was founded in 2002 and new infections have been reduced by 61%. In the absence of HIV prevention and HIV treatment measures and antiretroviral medicines, deaths would have increased by 115% and new HIV infections by 119% in the same period. The world has made remarkable progress in the response to HIV – we’ll work together to finish the fight by 2030.





Investing for Impact

The Global Fund provides 28% of all international financing for HIV programs and has invested a total of US$26.6 billion in programs to prevent and treat HIV and AIDS and US$5.5 billion in TB/HIV programs as of June 2024. Global Fund investments to tackle HIV not only drive progress against the disease, but also contribute to building strong, equitable and resilient health and community systems.

Today, we have the knowledge and tools to prevent every new HIV infection and each AIDS-related death. The gains made against HIV in 2023 build on more than two decades of acceleration and progress. The Global Fund partnership is now focused on finishing the fight against HIV and AIDS by 2030.


Progress Towards the Global Targets

Ending AIDS as a public health threat has never been more possible. Eswatini, for example, has achieved the 95-95-95 targets (95% of people living with HIV know their HIV status, 95% of people who know that they are living with HIV are on lifesaving antiretroviral therapy, and 95% of people who are on treatment are virally suppressed). Steadfast commitment from the government and the strong role of communities have been key in driving this progress.

But many countries are still off track to achieve the target of ending AIDS by 2030, particularly in relation to the number of new HIV infections still occurring. But by taking bold action now – which means supporting countries to ensure HIV services and programs are people-centered, promote human rights and gender equality, and are delivered in ways that maximize uptake, use and impact – we can reverse this trend and end AIDS by 2030.







In 2023, TB programs registered a complete recovery from the impact of COVID-19.

The significant recovery and acceleration in screening and testing we saw from 2022 has been sustained and efforts to find undiagnosed people have accelerated. Taken together with widening rollout of innovations and tools to enhance efficiency, strengthened commitments at the national and international level and progress in diagnostics, drugs and vaccine development – the outlook for TB is evolving in a hopeful and positive direction.


All data is based on estimates from Global Tuberculosis Report 2023. Global Fund disbursements are available on the Global Fund Data Explorer. Global Fund Regional Groupings.



But TB continues to be fueled by inequity, and millions of people continue to live with and die from TB without ever receiving a diagnosis. The disease killed an estimated 1.3 million people in 2022. 

In 2023, the Global Fund partnership continued to support countries to deliver equitable, people-centered, cost-effective TB interventions; prioritized finding and treating “missing” people with TB and drug-resistant TB; supported the rollout of better treatment regimens; increased the availability of people-centered, accessible, and quality screening and diagnostics; and addressed the structural drivers of TB and barriers to TB services, including gender and human rights challenges.


Trends in TB Burden

In countries where the Global Fund invests, TB deaths (excluding people living with HIV) have been reduced by 36% between 2002 and 2022, while new TB cases (all forms) have dropped by 1%. In the absence of TB control measures, deaths would have increased by 129% and TB cases by 38% in the same period.



Investing for Impact

The Global Fund provides 76% of all international financing for TB and has invested US$9.9 billion in programs to prevent and care for people with TB and US$1.9 billion in TB/HIV programs as of June 2024. Our investments in TB programs globally are reinforcing health and community systems, making them more resilient, sustainable and inclusive.



 To end TB as a public health threat, we must remain laser-focused on bridging the gaps in prevention, treatment and care that persist. 


Progress Towards the Global Targets

In 2023, TB programs in countries where the Global Fund invests achieved a complete recovery from COVID-19-related disruption. We found more people with TB than ever before – 7.1 million people were put on treatment.

Country efforts are at the center of this progress. India, which has the world’s largest TB burden, treated 2.4 million people1 for TB in 2023, up from 1.7 million just six years before. And as a result of strong domestic resource commitments to their TB program in recent years, Indonesia has been able to increase the number of people treated for TB from 339,000 in 2021 to 783,000 in 2023.

Despite that progress, we are still off track to end TB as a public health threat by 2030. To get there, we must do more. An all-in response to TB today actively contributes to building a safer, healthier and more equitable world tomorrow.

[1] https://www.who.int/teams/global-tuberculosis-programme/data#prov_notifications





Malaria remains a daunting global health challenge. Conflict, climate change and increasing resistance to insecticides are jeopardizing the significant gains that the Global Fund partnership has made against malaria over the last two decades. But with investments to strengthen health systems and accelerate the targeted deployment of innovative tools and trusted prevention, testing and treatment methods, the Global Fund partnership is fighting back.


All data is based on estimates from World Malaria Report 2023. Global Fund disbursements are available on the Global Fund Data ExplorerGlobal Fund Regional Groupings.


 



In 2023, Global Fund-supported malaria programs lent a special focus to reaching children under 5 and pregnant women, who are most vulnerable to severe malaria. In 2023, 44.6 million children received seasonal malaria chemoprevention and 15.5 million pregnant women received preventive treatment for malaria in countries where we invest. Posting a full recovery from COVID-19-related disruption, our partnership expanded access to powerful tools to prevent and treat malaria, including new dual-insecticide mosquito nets, seasonal malaria chemoprevention for children at high risk of malaria, intermittent preventive treatment of malaria for pregnant women, indoor residual spraying, and antimalarial medicines. 


Trends in Malaria Burden

Since 2010, countries with the highest malaria burden have achieved significant declines in the overall number of deaths and have been able to drive down incidence rates. In countries where the Global Fund invests, malaria deaths have reduced by 28% between 2002 and 2022. In the absence of malaria control measures, deaths would have increased by 90% and malaria cases by 79% in the same period. The malaria incidence rate has declined by 29% since 2002.




Investing for Impact

The Global Fund provides 62% of all international financing for malaria programs and has invested more than US$19.1 billion in malaria programs as of June 2024. The Global Fund’s investments in the fight against malaria are making far-reaching contributions to strengthening health and community systems, making them more resilient, sustainable and inclusive.



As proved by Cabo Verde – certified malaria-free by WHO in 2024 – the target of ending malaria is within reach. But we must work even harder to regain lost progress and ensure that crises such as conflict and climate change do not derail our efforts.





Progress Towards the Global Targets

Malaria remains a daunting global health challenge, and we are off track to meet the target of ending the disease as a public health threat by 2030. It is imperative to get back on track to fight malaria, to protect our gains and end this disease once and for all. With investments to accelerate the deployment of innovative tools, scale up interventions and strengthen critical health system capabilities, like disease surveillance, community health workers and last-mile logistics, we are fighting back.

 




Strengthening Health and Community Systems

We are investing more than ever before in building stronger health and community systems to support interventions to combat the three diseases, accelerate the path towards universal health coverage and reinforce preparedness against future threats, including pandemics, antimicrobial resistance and climate change. Our investments are supporting primary health care facilities, laboratories, supply chains, oxygen provision and community health workers. In 2023 alone, we invested US$1.8 billion2 in health and community systems.





As the largest multilateral grants provider for health systems strengthening, we are supporting countries to build more effective and resilient health delivery systems, including community systems that reach the poorest and most marginalized. We invest in strengthening health product value chains and securing increased supply capacity and lower health product prices through market shaping. In 2023, we invested US$142.4 million in expanding and strengthening laboratory and diagnostics capacities; US$98.6 million in surveillance systems to strengthen early detection and reporting capabilities for all hazards; and from 2021 to 2025, we are investing around US$564 million to expand access to lifesaving medical oxygen. The Global Fund has invested more than US$1.5 billion in community health workers since 2020 and is investing US$900 million more over the next three years.





Colliding Crises

In the face of crises and challenging circumstances, we have repeatedly demonstrated our value in supporting countries to adapt to shocks to ensure sustainable progress against the three diseases and improve overall health outcomes. 

In 2023, climate change, conflict, and attacks on human rights, gender equality and civil society caused enormous human suffering and deepened inequities within and between countries. While the impact and dynamics of these crises differ by region and country, the challenges invariably put the poorest and the most marginalized people at greater risk of deadly infectious diseases.

Since 2002, the Global Fund has provided more than US$22 billion to support crucial HIV, TB, and malaria prevention and treatment services and strengthen health and community systems in countries or regions that experience infectious disease outbreaks, natural disasters and hazards, armed conflicts or civil unrest, weak governance, climate change-related crises, and/or mass displacement.

To end HIV, TB and malaria as public health threats and address emerging dangers to global health security, we need to reach the most vulnerable people with prevention and treatment services, wherever they are.


Investing for Impact

The Global Fund galvanizes the world to invest in the fight against the deadliest infectious diseases while challenging the injustice that continues to fuel them. Since our founding in 2002, the Global Fund has disbursed more than US$65.4 billion to support programs run by local experts in more than 100 countries. In 2023, we invested US$5 billion3 to fight deadly infectious diseases and strengthen health and community systems. This is the third year in a row of record investments for the Global Fund.




Our Results Methodology

The Global Fund Results Report 2024 presents selected programmatic results (e.g., people on antiretroviral therapy, people treated for TB, mosquito nets distributed) achieved by supported programs in 2023. The programmatic results are reported routinely to the Global Fund by the supported programs. The data collected by our technical partners are also used for cross-checking and triangulation and for furnishing national data for selected services to align with the Global Fund partnership’s approach in results reporting. The Global Fund also uses official disease burden and impact estimates developed and published by our technical partners, including the World Health Organization and UNAIDS, as the basis for measuring impact.

Learn more >



[2] This includes direct investments in resilient and sustainable systems for health (RSSH) and contributions to RSSH through investments in the fight against HIV, TB and malaria.
[3] When including Strategic Initiative disbursements, this figure would amount to US$5.1 billion.




In the fight to defeat AIDS, tuberculosis and malaria, we must #LeaveNoOneBehind.

For Hee Jeong Han, this means ending the inequities that continue to determine who lives and who dies.

@gfadvocates | @han_heejeong_kagh 


https://www.instagram.com/reel/C3AtglIyH0j/?utm_source=ig_web_copy_link&igsh=MzRlODBiNWFlZA==

글로벌펀드는 저소득 및 중간 소득 100여개의 국가에 총 40억 달러(2020년 3월-2021년 10월)를 지원했다고 발표하였습니다.

 

에이즈, 결핵 및 말라리아 퇴치를 위한 글로벌펀드(Global Fund to Fight AIDS, Tuberculosis and Malaria, 이하 글로벌펀드)는 코로나19와 싸우고 에이즈, 결핵, 말라리아 프로그램을 적용/운영 시키기 위해 100개 이상의 저소득 및 중간 소득 국가에 총 40억 달러를 지원했다고 발표했습니다. 이 지원금은 이 외에도 시급한 취약한 보건 의료 시스템 강화에도 사용될 예정입니다. 이 기금으로 글로벌펀드가 에이즈, 결핵 및 말라리아 퇴치를 위해 국가에 연간 제공하는 42억 달러 외에 추가로 지급된 지원금 입니다. 


글로벌펀드는 지난 2021년 3월 이후로, 미국, 독일, 네덜란드, 스위스 등의 국가들의 주도로 마련된 코로나19 대응 메카니즘(C19RM, COVID-19 Response Mechanism) 기금 명목으로 저소득 및 중소득국가에 30억 달러를 지원한 바 있습니다. 


“글로벌펀드가 최근에 발간한 2021 결과보고서는 코로나19가 그동안 에이즈, 결핵, 및 말라리아 프로그램에 얼마나 심각한 악영향을 미쳤는지를 보여주었습니다. 그러나 글로벌펀드 파트너십이 이 전염병들 전반에 걸쳐 취한 신속하고 단호한 조치가 없었다면 현재 상황은 훨씬 더 나빴을 것입니다." (피터샌즈 글로벌펀드 사무총장) 

[원문] https://www.theglobalfund.org/en/news/2021/2021-10-08-global-fund-crosses-usd4-billion-mark-in-funding-to-support-countries-in-the-fight-against-covid-19/


[출처] 국제보건애드보커시 블로그(https://blog.naver.com/koreanagh/222534961354)


◎ 에이즈, 결핵 및 말라리아 프로그램에 대한 코로나19의 치명적인 영향


오늘 글로벌펀드(GlobalFund)가 발표한 새로운 보고서에 따르면 코로나19 대유행은 2020년 에이즈, 결핵 및 말라리아 퇴치에 치명적인 영향을 미쳤습니다. 결과 보고서에 따르면 일부 진전은 있었지만 주요 (에이즈, 결핵, 말라리아) 프로그램 결과는 글로벌펀드 역사상 처음으로 하락했습니다.


"창립 20주년을 기념하하여 우리는 지난 20년 동안의 에이즈, 결핵 및 말라리아에 있어 글로벌펀드가 달성한 진전과 그를 가능하게 한 용기와 회복력의 놀라운 이야기들에 초점을 두어 보고서를 발간하고자 희망했습니다." 피터샌즈 글로벌펀드 사무총장은 언급하였습니다. “그러나 2020년도 조사 결과는 다른 초점을 강요합니다. 조사 결과들은 코로나19로 인해 발생할까 두려워했던 일을 확인시켜주었습니다.”


<<결핵(TB)>> 결과 보고서는 코로나19 전염병이 전 세계 결핵 퇴치에 미친 치명적인 영향을 보여줍니다. 2020년에 글로벌펀드가 투자하는 국가에서 약물 내성 결핵 치료를 받는 사람들의 수는 19%나 감소했으며, 광범위 약물 내성 결핵 치료를 받는 사람들은 37%가 더 크게 감소했습니다. 항레트로바이러스 치료와 결핵 치료를 받은 에이즈 양성 결핵 환자의 수는 16% 감소했습니다.


<<에이즈(HIV)>> 보고서는 또한 이미 불균형적으로 영향을 받은 주요 및 취약 인구를 위한 에이즈 검사 및 예방 서비스의 상당한 감소를 강조합니다. 2019년에 비해 에이즈 예방 프로그램 및 서비스를 받은 사람은 11% 감소한 반면 예방 서비스를 받은 젊은이는 12% 감소했습니다. 아기에게 에이즈를 전염시키는 것을 방지하기 위해 약을 복용하는 산모는 4.5% 감소했습니다. 에이즈 검사는 22% 감소하여 대부분의 국가에서 에이즈 치료 시작을 지연시켰습니다.


<<말라리아(Malaria)>> 말라리아 퇴치를 위한 개입은 다른 두 질병보다 코로나19의 영향을 덜 받은 것으로 보입니다. 적응 조치와 지역 사회 보건 종사자의 근면 및 혁신 덕분에 예방 활동은 2019년에 비해 안정적이거나 증가했습니다. 모기장 배포 수는 17% 증가, 실내 잔류 살포로 덮인 구조물은 3% 증가했습니다. 2020년에는 1,150만 명의 임산부가 예방 치료를 받았습니다. 그러나 테스트한 말라리아 의심 사례는 4.3% 감소했고 질병에 대한 진행도 정체되었습니다.


코로나19에 대한 글로벌펀드 파트너십의 신속하고 단호한 대응은 더 나쁜 결과를 예방했습니다. 2020년에 글로벌펀드는 에이즈, 결핵 및 말라리아 퇴치를 계속하고 보건·의료시스템을 강화하기 위해 42억 달러를 지출했으며 코로나19에 대응하기 위해 9억 8천만 달러를 추가로 승인했습니다. 2021년 8월 현재 글로벌펀드는 인명 구조 에이즈, 결핵 및 말라리아 프로그램에 적응하고, 중요한 검사, 치료 및 의료 용품을 제공하고, 최전선 의료 종사자를 보호하고 취약한 사람들을 긴급하게 지원하기 위해 100개 이상의 국가에 총 33억 달러를 승인했습니다. 기부자, 정부, 지역 사회 및 보건·의료 파트너의 신속한 조치 및 자금 지원과 함께 이러한 투자는 코로나19가 에이즈, 결핵 및 말라리아에 미치는 영향을 완화하고 세 가지 질병과의 싸움에서 진전을 이루는 데 도움이 되었습니다.


<< 글로벌펀드가 투자하는 국가들의 2020년 (에이즈,결핵,말라리아 및 코로나19 대응 관련) 주요 결과 >>

• 2020년에 2,190만 명이 생명을 구하는 HIV에 대한 항레트로바이러스 치료를 받았으며, 이는 COVID-19에도 불구하고 2019년에 비해 8.8% 증가한 수치입니다.

• 2020년에 870만 명이 HIV 예방 서비스에 도달했습니다.

• 2020년에 470만 명이 결핵 치료를 받았습니다.

• 2020년에 결핵 환자와 접촉한 194,000명의 어린이가 예방 치료를 받았습니다.

• 말라리아로부터 가족을 보호하기 위해 배포된 모기장 1억 8,800만 개는 COVID-19에도 불구하고 2019년에 비해 17% 증가한 수치입니다.


“글로벌펀드 파트너십은 계속해서 생명을 구하고 있습니다. 코로나19 전염병으로 인한 특별한 도전에 직면한 우리의 파트너십은 유연성과 결단력을 보이며 전 세계 수백만 명의 사람들에게 의약품, 물품 및 치료를 제공했습니다. 우리가 지원하는 국가는 에이즈, 결핵 및 말라리아 퇴치를 위해 만들어진 동일한 실험실, 질병 감시, 커뮤니티 네트워크, 훈련된 의료 종사자 및 공급망을 사용하여 코로나19에도 신속하게 대응했습니다.”라고 피터 샌즈 글로벌펀드 사무총장은 이야기 하였습니다.


2002년 창립 이래 글로벌펀드 파트너십은 4,400만 명의 생명을 구했습니다. 글로벌펀드가 투자하는 국가에서 에이즈, 결핵 및 말라리아로 인한 사망자 수는 46% 감소했습니다. 이러한 성과는 시행 정부, 다자 기관, 양자 파트너, 시민 사회 단체, 질병의 영향을 받는 사람들 및 민간 부문을 포함하여 글로벌펀드 파트너십을 구성하는 다양한 행위자들의 노력의 결과입니다.


피터 샌즈 글로벌펀드 사무총장은 "코로나19로 인한 끔찍한 피해에도 불구하고 팬데믹은 우리에게 더 나은, 더 평등하고 건강한 세상을 건설할 기회를 제공한다"고 결론지었다. “우리는 함께 에이즈, 결핵, 말라리아의 궤적을 바꾸었고 앞으로도 계속 싸워 나갈 것 입니다." 라고 밝혔습니다.


"그렇게 글로벌, 국가 및 지역 수준에서 혁신과 협력을 계속한다면 에이즈, 결핵 및 말라리아를 종식시키고 코로나19를 물리치고 전염병 대비 및 대응을 위한 훨씬 더 강력한 기반을 구축할 수 있습니다.”


[출처] 국제보건애드보커시 블로그(https://blog.naver.com/koreanagh/222499014657)